Batazu Advanced Therapeutics is advancing BAT-33/CLL1, a dual-target CAR T cell therapy candidate designed for patients with relapsed or refractory Acute Myeloid Leukaemia. The company is working with European partners to complete preclinical development and prepare for first-in-human studies.